Nuvation Bio Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $169.9M+2,058.0% YoYTTM through 30 Jun 2026
Net Income -$149.8MTTM through 30 Jun 2026
Free Cash Flow -$128.5MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| EBITDA Margin | -79.7% |
| Operating Margin | 11.7% |
| Net Margin | -88.2% |
Returns
-59.0%ROE
-20.1%ROA
Balance Sheet Health
Debt / Equity0.96x
Current Ratio8.37x
Net Debt-$16Mnet cash position
Cash & Equivalents$258.6M
Quality Metrics
Altman Z-Score1.06
Piotroski F-Score5 / 9
FCF Margin-75.6%
Rule of 40-57.3
Earnings-Beat Rate50.0%
Multi-Year Trend
RevenueFY2025: $62.9M
Diluted EPS-$0.44TTMFY2025: $-599.13
Dividend
No dividend
Capital Allocation
R&D Spend$128.9M
Capex Intensity4.7%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Product Revenue, Net (IBTROZI) | $18.5M | View detailsContinued commercial adoption in the U.S. as the preferred TKI for ROS1+ NSCLC across treatment lines. | |
| Collaboration and License Agreements | $64.7M | View detailsEisai partnership will drive development, registration, and commercialization of taletrectinib in Europe and other global territories. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.